Business description: Evotec SE

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Number of employees: 5,055

Sales by Activity: Evotec SE

Fiscal Period: December20192020202120222023

EVT Execute

420M 489M 610M 736M 739M

EVT Innovate

94.33M 106M 147M 205M 267M

Transition

14.5M 21.84M - - -

Intersegment Elimination

-82.7M -116M -139M -189M -224M
See all business segments

Geographical breakdown of sales: Evotec SE

Fiscal Period: December20192020202120222023

USA

195M 248M - - 459M

Rest of the World

82.68M 77.71M - - 95.15M

United Kingdom

77.9M 93.99M - - 86.37M

Switzerland

- - - - 64.92M

Germany

27.98M 44.32M - - 34.13M

France

62.83M 37.06M - - 32M
See all geographic segments

Managers: Evotec SE

Manager TitleAgeSince
Director of Finance/CFO 51 07/23/07
Chief Operating Officer 54 01/12/01
Chief Tech/Sci/R&D Officer 60 01/10/01
Investor Relations Contact - -
Corporate Officer/Principal 51 01/22/01
See EVOTEC SE governance

Members of the board: Evotec SE

Director TitleAgeSince
Chairman 63 17/14/17
Director/Board Member 56 19/19/19
Director/Board Member 62 01/21/01
Director/Board Member 41 22/22/22
Composition of the Board of Directors

Shareholders: Evotec SE

NameEquities%Valuation
T. Rowe Price International Ltd.
9.819 %
17,432,691 9.819 % 168 M €
Novo Holdings A/S (Investment Company)
8.410 %
14,931,858 8.410 % 144 M €
Mubadala Investment Co. (Investment Company)
5.172 %
9,182,652 5.172 % 88 M €
1,514,826 0.8532 % 15 M €
Franklin Bissett Investment Management
0.7322 %
1,300,000 0.7322 % 13 M €
NameEquities%Valuation
Mubadala Investment Co. (Investment Company)
5.179 %
4,597,701 5.179 % 22 M €
Morgan Stanley Capital Services LLC
0.0987 %
87,606 0.0987 % 420 509 €
Millennium Management LLC
0.0933 %
82,815 0.0933 % 397 512 €
DCF Advisers LLC
0.0538 %
47,797 0.0538 % 229 426 €
Optiver Holding BV
0.0468 %
41,507 0.0468 % 199 234 €
List of EVOTEC SE shareholders

Holdings: Evotec SE

NameEquities%Valuation
14,035,200 11.86% 71,579,520 $

Company details: Evotec SE

Evotec SE

Manfred Eigen Campus Essener Bogen 7

22419, Hamburg

+49 40 560 81 0

http://evotec.com
address Evotec SE(EVT)

Group companies: Evotec SE

NameCategory and Sector
Miscellaneous Commercial Services
Miscellaneous Commercial Services
Miscellaneous Commercial Services
Pharmaceuticals: Major
See all subsidiaries

Other Biotechnology & Medical Research

Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-1.46%+1.27%-63.77%-75.71% 1.72B
-0.08%-1.61%+0.09%-64.70% 46.95B
-1.79%+3.69%+5.87%-3.02% 44.71B
+1.60%+1.40%+7.39%-26.11% 41.67B
-0.01%-5.59%+22.64%+29.30% 29.8B
-2.07%+0.26%+25.30%-25.53% 28.65B
-0.52%-2.21%+39.53%+55.30% 28.11B
+0.65%+2.07%+36.32%+81.50% 14.76B
-18.31%-21.25%+45.83%+97.73% 13.51B
-0.26%-2.46%-11.43%-34.35% 12.26B
Average -2.10%-0.02%+10.78%+3.44% 26.21B
Weighted average by Cap. -1.17%+0.43%+15.23%-2.26%
See all sector performances